Genmab A/S (GMAB) is a Biotechnology company in the Healthcare sector, currently trading at $29.06. It has a SharesGrow Score of 76/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of GMAB = $10.40 (-64.2% from the current price, the stock appears overvalued). Analyst consensus target is GMAB = $42 (+45% upside).
Valuation: GMAB trades at a trailing Price-to-Earnings (P/E) of 4.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.1.
Financials: revenue is $3.7B, -13.1%/yr average growth. Net income is $964M, growing at -9.2%/yr. Net profit margin is 25.9% (strong). Gross margin is 91.7% (-8.3 pp trend).
Balance sheet: total debt is $5.4B against $5.8B equity (Debt-to-Equity (D/E) ratio 0.93, moderate). Current ratio is 2.02 (strong liquidity). Debt-to-assets is 42.2%. Total assets: $12.8B.
Analyst outlook: 12 / 17 analysts rate GMAB as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 15/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 65/100 (Partial), Future 85/100 (Pass), Income 85/100 (Pass).
